Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Pharming Group guidance cut and half year results draw investor focus
Pharming Group (ENXTAM:PHARM) has drawn fresh attention after lowering its 2026 revenue guidance by US$30 million and reporting half year 2026 results that showed reduced sales but a smaller net loss.
See our latest analysis for Pharming Group.
Pharming Group's guidance cut and half year 2026 results appear to have fed into weaker sentiment, with the stock's share price down 26.76% over 30 days and a 1 year total shareholder return of 5.37% in decline from prior levels.
If this kind of news has you reassessing where growth or resilience might come from next, it could be worth scanning for opportunities in AI driven health stocks through the 128 healthcare AI stocks
The guidance reset and sharp share price fall now leave Pharming Group trading at a steep discount to both analyst targets and an estimated fair value. Is that a clear mispricing, or a fair reflection of the risks ahead?
Most Popular Narrative: 62.8% Undervalued
The most followed narrative on Pharming Group compares a fair value of €2.36 to the last close of €0.88. It frames a wide gap that hinges on rare disease growth drivers and long term cash flows.
Ongoing double-digit growth of RUCONEST in severe HAE patients, supported by its differentiated clinical profile and limited competitive impact in this high-need niche, is likely to sustain a durable cash engine and support continued revenue expansion and stable to improving gross margins.
Curious what has to happen for that gap between price and fair value to close. The narrative leans heavily on multi year revenue compounding, margin uplift and a rich future earnings multiple. Want to see exactly which assumptions do the heavy lifting in this €2.36 figure.
Result: Fair Value of €2.36 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Pharming Group narrative still faces meaningful risk if Joenja label expansions are delayed or if hereditary angioedema competition gradually eats into RUCONEST volumes.
Find out about the key risks to this Pharming Group narrative.
Another view on Pharming Group's valuation
The earlier Pharming Group narrative leans on discounted future cash flows and points to a wide gap between price and fair value. On current numbers though, the stock trades on a P/E of 76.9x versus 35.5x for peers and a fair ratio of 44.8x, which suggests a high bar if earnings stumble.
For investors, that raises a simple question: Is this a rare chance to buy misunderstood growth, or just paying up for forecasts that may not fully play out?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment on Pharming Group split between concern and optimism, it may be useful to review the full picture for yourself using the 4 key rewards and 2 important warning signs .
Looking for more Pharming Group style investment ideas?
If Pharming Group has you rethinking where to focus next, it makes sense to broaden your watchlist using structured stock ideas rather than chasing headlines.
Use the Simply Wall St Screener to quickly compare potential opportunities and keep your shortlist aligned with your own goals and risk comfort.
-
Target potential upside by scanning companies highlighted in the 259 high quality undervalued stocks . These combine quality fundamentals with prices below their estimated worth.
-
Strengthen your income stream by shortlisting stocks from the 433 dividend fortresses , which focuses on higher yields with an emphasis on resilience.
-
Prioritise capital preservation by filtering companies in the 303 resilient stocks with low risk scores , which emphasises stability over aggressive growth.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PHARM.AS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
